HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients

Antimicrob Agents Chemother. 2012 Jul;56(7):3981-3. doi: 10.1128/AAC.00507-12. Epub 2012 Apr 30.

Abstract

We analyzed the evolution of viral tropism after 8 days of maraviroc monotherapy, i.e., we used the maraviroc clinical test (MCT), in 21 patients with and 14 without virological response to the drug (MCT(+) and MCT(-) patients, respectively). No increases in CXCR4 inferred viral loads (X4IVLs) were observed in MCT(+) patients, while X4IVLs increased only in MCT(-) patients, with X4IVLs of >2 log(10) HIV RNA copies/ml. These results shed light on the evolution of viral tropism under a CCR5 antagonist in vivo.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • CCR5 Receptor Antagonists
  • CD4-Positive T-Lymphocytes / metabolism
  • Cyclohexanes / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV Infections / virology*
  • Humans
  • Maraviroc
  • Receptors, CXCR4 / metabolism
  • Triazoles / therapeutic use*
  • Viral Load / drug effects

Substances

  • Anti-HIV Agents
  • CCR5 Receptor Antagonists
  • CXCR4 protein, human
  • Cyclohexanes
  • Receptors, CXCR4
  • Triazoles
  • Maraviroc